#1 Clinical Trials Search in Europe

Lifileucel

Lifileucel is an innovative immunotherapy being studied in clinical trials for the treatment of advanced melanoma. This therapy uses a patient’s own tumor-infiltrating lymphocytes (TILs) to fight cancer cells. The ongoing trials aim to evaluate the safety and effectiveness of lifileucel, both as a standalone treatment and in combination with other immunotherapies, for patients with unresectable or metastatic melanoma.

Table of Contents

What is LIFILEUCEL?

LIFILEUCEL, also known as LN-144, is an innovative cancer treatment classified as a cell therapy[1]. It belongs to a category of treatments called autologous tumor-infiltrating lymphocytes (TIL). This means that the therapy uses the patient’s own immune cells, specifically T lymphocytes, which are extracted from the tumor tissue, expanded in the laboratory, and then reinfused back into the patient[1][2].

How does LIFILEUCEL work?

LIFILEUCEL works by harnessing the power of the patient’s own immune system to fight cancer. Here’s a simplified explanation of the process:

  1. A sample of the patient’s tumor is surgically removed.
  2. T lymphocytes (a type of white blood cell) are extracted from the tumor tissue.
  3. These T cells are then grown and multiplied in a laboratory.
  4. The expanded population of T cells is infused back into the patient.
  5. These reinfused T cells are primed to recognize and attack cancer cells throughout the body.

This approach is designed to provide a more targeted and personalized treatment for cancer patients[1][2].

What conditions does LIFILEUCEL treat?

LIFILEUCEL is primarily being studied for the treatment of:

  • Advanced melanoma: This includes unresectable or metastatic melanoma (Stage IIIC to IV)[1][2].
  • Head and neck squamous cell carcinoma (HNSCC): Advanced, recurrent, or metastatic cases[2].
  • Non-small cell lung cancer (NSCLC): Stage III or Stage IV[2].

It’s important to note that LIFILEUCEL is still under investigation for these conditions and is not yet approved for general use outside of clinical trials.

Clinical Trials and Effectiveness

LIFILEUCEL is currently being evaluated in several clinical trials to assess its safety and efficacy. Some key points about these trials include:

  • A Phase 3 trial is comparing LIFILEUCEL in combination with pembrolizumab (an immunotherapy drug) to pembrolizumab alone in patients with untreated, unresectable, or metastatic melanoma[1].
  • The primary measure of effectiveness in these trials is the objective response rate (ORR), which refers to the proportion of patients whose cancer shrinks or disappears after treatment[2].
  • Other important measures include progression-free survival (PFS) and overall survival (OS)[1][2].

While final results are still pending, early data from these trials suggest that LIFILEUCEL may be a promising treatment option for patients with advanced solid tumors, particularly those who have not responded to other therapies.

Administration and Treatment Process

The LIFILEUCEL treatment process involves several steps:

  1. Tumor resection: A portion of the patient’s tumor is surgically removed.
  2. TIL production: The tumor-infiltrating lymphocytes are extracted and multiplied in a laboratory.
  3. Preparative regimen: Patients receive a combination of drugs (called NMA-LD) to prepare their body for the cell infusion.
  4. TIL infusion: The expanded TILs are infused back into the patient.
  5. Post-infusion therapy: Patients receive interleukin-2 (IL-2) to support the growth and function of the infused T cells[1][2].

The entire process, from tumor resection to TIL infusion, can take several weeks.

Potential Side Effects and Safety Considerations

As with any cancer treatment, LIFILEUCEL may cause side effects. Some potential side effects include:

  • Reactions to the preparative regimen or IL-2 therapy
  • Increased risk of infections due to temporarily lowered immune function
  • Fatigue
  • Nausea
  • Potential autoimmune reactions

It’s important to note that the full safety profile of LIFILEUCEL is still being evaluated in ongoing clinical trials[1][2].

Who is eligible for LIFILEUCEL treatment?

Eligibility for LIFILEUCEL treatment in clinical trials typically includes:

  • Patients aged 18 and older with confirmed advanced melanoma, HNSCC, or NSCLC
  • Patients with measurable disease and at least one tumor that can be safely removed for TIL production
  • Adequate organ function and overall health status
  • No active infections or certain autoimmune disorders
  • No history of certain other cancers or treatments that might interfere with the therapy[1][2]

Specific eligibility criteria may vary depending on the particular clinical trial.

Future Prospects and Ongoing Research

LIFILEUCEL represents an exciting development in the field of cancer immunotherapy. Ongoing research aims to:

  • Determine the most effective combinations of LIFILEUCEL with other therapies
  • Explore its potential in treating other types of solid tumors
  • Improve the manufacturing process to make the treatment more widely available
  • Identify biomarkers that could predict which patients are most likely to benefit from the therapy[1][2]

As research progresses, LIFILEUCEL may become an important addition to the arsenal of treatments available for patients with advanced cancers.

Aspect Details
Treatment Lifileucel (LN-144), an autologous tumor-infiltrating lymphocyte therapy
Condition Unresectable or metastatic melanoma
Trial Phase Phase 2 and Phase 3 studies
Administration Dispersion for infusion (intravenous)
Primary Objectives Evaluate efficacy (tumor response) and safety profile
Key Endpoints Progression-free survival, overall survival, objective response rate
Combination Therapy Studied alone and in combination with checkpoint inhibitors (e.g., pembrolizumab)
Patient Eligibility Adults with confirmed diagnosis, adequate organ function, measurable disease

FAQ

  • What is lifileucel? Lifileucel is a type of immunotherapy that uses a patient's own tumor-infiltrating lymphocytes (TILs) to fight cancer cells. It's being studied as a treatment for advanced melanoma.
  • How is lifileucel administered? Lifileucel is administered as a dispersion for infusion, which means it's given directly into the bloodstream through an intravenous (IV) line.
  • Who is eligible for lifileucel clinical trials? Eligibility varies, but generally includes adults with unresectable or metastatic melanoma who have adequate organ function and no active infections. Specific trials may have additional criteria.
  • What are the main goals of the lifileucel clinical trials? The main goals are to evaluate the safety of lifileucel and its effectiveness in treating advanced melanoma, measured by factors such as tumor response rate and progression-free survival.
  • Are there any side effects associated with lifileucel treatment? While specific side effects are still being studied, patients may experience reactions related to the infusion or the immune system's response. The trials closely monitor patients for any adverse events.

Ongoing Clinical Trials on Lifileucel

  • Study on the Effectiveness and Safety of Lifileucel and Pembrolizumab for Patients with Untreated, Unresectable, or Metastatic Melanoma

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Czechia Finland France Germany Greece +6

  • A Study of Lifileucel with Cyclophosphamide, Fludarabine, and Aldesleukin for Adults with Previously Treated Advanced Melanoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study of LN-144 and LN-145 (Tumor Infiltrating Lymphocytes) in patients with solid tumors, including melanoma, head and neck cancer, and non-small cell lung cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Greece Spain

Glossary

  • Lifileucel: An immunotherapy treatment that uses a patient's own tumor-infiltrating lymphocytes (TILs) to fight cancer cells, specifically being studied for advanced melanoma.
  • Tumor-infiltrating lymphocytes (TILs): Immune cells found in tumors that can recognize and attack cancer cells.
  • Unresectable: Describing a tumor that cannot be completely removed through surgery.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.
  • Response Evaluation Criteria in Solid Tumors (RECIST): A standard way to measure how well a cancer patient responds to treatment.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Checkpoint inhibitors (CPIs): A type of immunotherapy that helps the immune system recognize and attack cancer cells more effectively.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-lifileucel-and-pembrolizumab-for-patients-with-untreated-unresectable-or-metastatic-melanoma/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-benefits-of-ln-144-and-ln-145-for-patients-with-metastatic-melanoma-head-and-neck-cancer-and-non-small-cell-lung-cancer/